Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Atopic dermatitis and the skin microbiome

How does systemic therapy influence dysbiosis?

    • Congress Reports
    • Dermatology and venereology
    • RX
    • Studies
  • 6 minute read

One aim of the multicenter observational study ProRaD is to gain a better understanding of the mechanisms that influence the course of atopic dermatitis (AD). In a sub-project, researchers used modern sequencing technologies to investigate the effects of system therapeutics on the skin microbiome in AD patients. It is hoped that research projects such as these will optimize treatment strategies for AD.

Microbiome research (Greek mikrós “small” and bios “life”) has increasingly become the focus of interest in recent years and the methods of molecular analysis of microbial populations are constantly being further developed [1]. Nowadays, next-generation sequencing (NGS) is often used as a measurement method in microbiome analyses [1]. NGS can be used to determine the identities of bacteria, fungi and other microorganisms in a sample in the form of genome segments and to estimate the relative frequencies with which they are represented in it [2]. Intensive and systematic research into the human cutaneous and intestinal microbiome using NGS was carried out, for example, as part of the “Human Microbiome Project”, an initiative of the US National Institutes of Health [3]. In the meantime, NGS has been used in numerous studies to investigate the microbiome and interesting insights have been gained into the skin microbiome in atopic dermatitis (AD) [4]. Particularly during an acute attack of AD, a greatly reduced bacterial diversity of the microbiota and a high relative abundance of Staphylococcus aureus (S. aureus) can be observed [5].

Microbiome analyses as part of the ProRaD collective

In order to investigate the effect of local and systemic therapeutics on the human skin microbiome in patients with AD, skin samples were collected and analyzed as part of the prospective longitudinal study ProRaD in Augsburg and Bonn between 2017 and 2019 [6].

Methods: The researchers analyzed and evaluated a total of 1077 skin microbiome swabs and drug treatment data from 462 subjects in a cross-sectional study design. The skin microbiome of the patients was recorded using 16S rRNA amplicon sequencing of the V1-V3 region**. The “AnnotIEM” algorithm was used for the bioinformatic analysis, which compares the RNA sequence of the bacteria with numerous databases, allowing the subsequent determination of the individual microbiome down to the specific bacterial level with high accuracy [1,6].

** The composition of the microbiota can be determined by sequencing the variable regions (V1-V9) of the bacterial 16S rDNA. www.gtl.hhu.de/verfuegbare-workflows-proben request/next-generation-sequencing/microbiome-profiling-16s-amplicon sequencing

The current AD treatment regimen was documented and the patients were divided into treatment groups according to the recommendations of the EuroGuiDerm guidelines [6].

Analysis results: A strong correlation between skin condition and the frequency of S. aureus in skin lesions of AD patients was confirmed. No correlation between the relative abundance of S. aureus and age or sex was found. In order to exclude the skin condition as a confounding factor, separate examinations of the skin microbiome were carried out for mild, moderate and severe courses of the disease. In patients with moderate AD, there was a significantly lower relative abundance of S. aureus in those who received systemic therapy compared to those who received only topical treatment. In addition, the AD patients treated with systemic drugs tended to differ depending on the systemic drug administered. The average relative abundance of S. aureus was found to be lower in participants receiving therapy with the biologic (bDMARD) dupilumab compared to participants receiving systemic therapy with conventional immunosuppressants (csDMARD).

Conclusion : This pilot study described possible associations between AD treatment and microbiome changes within the ProRaD cohort. The results demonstrate the relevance of specific immunological processes in the microbial interplay in AD and point to the associated implications for system-therapeutic treatment. In particular, there were indications that treatment with dupilumab has a favorable effect on the dysbiosis associated with AD.

The microbiome also normalized under dupilumab in TREATgermany

Hartmann et al. reported on a study published in the journal “Allergy” in 2023, which investigated how the skin microbiome in AD is influenced by various system therapies [7].

Methodology: For their analysis, the researchers used a data set from the TREATgermany register study. Skin swabs from 157 AD patients were analyzed by 16S rRNA amplicon sequencing before and after three months of treatment with dupilumab or ciclosporin and compared with 258 population-based healthy controls. The severity of the disease was assessed using established instruments such as the “Eczema Area and Severity Index” (EASI) [15].

Analysis results: This study also confirmed a high relative abundance of S. aureus correlated with AD severity (EASI). Treatment with dupilumab led to a shift in microbial colonization towards a pattern similar to that observed in healthy controls. In the course of treatment, the relative frequency of Staphylococcus and especially S. aureus decreased significantly on both lesional and non-lesional AD skin, while the frequency of Staphylococcus hominis increased. These changes were largely independent of the degree of clinical improvement and were not observed during treatment with cyclosporine.

Conclusion: In the present analyses, systemic treatment with dupilumab tended to normalize the skin microbiome in AD in contrast to ciclosporin. This was found to be largely independent of the clinical response, suggesting that the IL-4 receptor alpha blockade induced by dupilumab per se may have an impact on the microbiome, the study authors said. However, further empirical studies are required to find out more about this [7].

Hypotheses on the underlying mechanisms

According to Hartmann et al. the blockade of type 2 cytokines can have direct and/or indirect effects on the composition of the skin microbiome [7]. Direct effects relate to skin barrier function and include, for example, normalization of epidermal lipid composition, increased levels of natural moisturizing peptides and increased production of antimicrobial peptides accompanied by reduced uptake of S. aureus [8–10] or a tendency for increased S. aureus clearance [11,12]. However, the experimental setup described in the analysis of the TREATgermany dataset does not allow any clear conclusions to be drawn about direct interactions, according to Hartmann et al. It therefore remains unclear whether the changes in the composition of the microbiome observed with dupilumab are a result of direct drug-specific effects and/or indirect effects of reduced cutaneous inflammation. Patients with a response >EASI90 showed the most pronounced recovery of bacterial diversity, which was comparable to that of healthy controls except for a residual microbial signature characterized by the presence of only a few AD-associated amplicon sequence variants (ASV) at different frequencies.

Congress: ADF Annual Meeting

Literature:

  1. CK-CARE, Center for Allergy Research and Education, Annual Report 2019, https://ck-care.ch/wp-content/uploads/2021/09/CKC_Jahresbericht_2019_web.pdf,(last accessed 17.05.2024)
  2. “Mikrobiomanalyse unter Berücksichtigung biologischer Datenstruktur”, https://opendata.uni-halle.de/bitstream/1981185920/64498/1/antweiler_
    Kai-Lars_Dissertation_2021.pdf
    , (last accessed 17.05.2024)
  3. Human Microbiome Project Consortium: Structure, function and diversity of the healthy human microbiome. Nature 2012; 486(7402): 207-214.
  4. Wollina U: Microbiome in atopic dermatitis. Clin Cosmet Investig Dermatol 2017; 10: 51-56.
  5. Fölster-Holst R: Die Rolle des Hautmikrobioms bei atopischer Dermatitis – Zusammenhänge und Konsequenzen. Journal der Deutschen Dermatologischen Gesellschaft 2022; 20(5): 571–578.
  6. Rohayem R, et al.: Targeted systemic treatment modulates the relative abundance of staphylococcus aureus in patients with atopic dermatitis, P119. 50th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF). Exp Dermatol 2024; 33(3): e14994.
  7. Hartmann J; TREATgermany Study Group. Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate-to-severe atopic dermatitis. Allergy 2023; 78(8): 2290–2300.
  8. Rohner MH, et al.: Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis. Allergy 2021; 76: 1268–1270.
  9. Miyake R, et al.: Uptake of Staphylococcus aureus by keratinocytes is reduced by interferon–fibronectin pathway and filaggrin expression. J Dermatol 2022; 49: 1148–1157.
  10. Hönzke S, et al.: Influence of Th2 cytokines on the cornified envelope, tight junction proteins, and β-defensins in filaggrin-deficient skin equivalents. J Invest Dermatol 2016; 136: 631–639.
  11. Möbus L, et al.: Atopic dermatitis displays stable and dynamic skin transcriptome signatures. J Allergy Clin Immunol 2021; 147: 213–223.
  12. Ferraro A, et al.: Role and plasticity of Th1 and Th17 responses in immunity to Staphylococcus aureus. Hum Vaccin Immunother. 2019; 15: 2980–2992.
  13. Moskovicz V, Gross A, Mizrahi B: Extrinsic Factors Shaping the Skin Microbiome. Microorganisms 2020, 8, 1023. www.mdpi.com/2076-2607/8/7/1023#,(last accessed 17.05.2024)
  14. Kim JE, Kim HS: Microbiome of the Skin and Gut in Atopic Dermatitis (AD): Understanding the Pathophysiology and Finding Novel Management Strategies. Journal of Clinical Medicine 2019; 8(4): 444.
    www.mdpi.com/2077-0383/8/4/444#,(last accessed 17.05.2024).
  15. Hanifin JM, et al.: The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10(1): 11–18.

DERMATOLOGIE PRAXIS 2024; 34(3): 36–37 (published on 14.6.24, ahead of print)

Autoren
  • Mirjam Peter, M.Sc.
Publikation
  • DERMATOLOGIE PRAXIS
Related Topics
  • ADF Annual Conference
  • Atopic dermatitis
  • Dysbiosis
  • Observational study
  • Prevention
  • ProRaD
  • Sequencing technologies
  • skin microbiome
  • system therapeutics
  • System therapy
  • Therapy
Previous Article
  • Sponsored Content: Extra-musculoskeletal manifestations in rheumatic diseases

Rheumatic diseases and their connection to the gut

  • Gastroenterology and Hepatology
  • Partner Content
  • Rheumatology
  • RX
View Post
Next Article
  • "Small Molecules" at AD

Current analyses of the pioneer among the JAK-i

  • Congress Reports
  • Dermatology and venereology
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 12 min
  • Evidence, effectiveness and practical implications

Medicinal plants for allergic rhinitis

    • RX
    • Allergology and clinical immunology
    • Education
    • General Internal Medicine
    • ORL
    • Pharmaceutical medicine
    • Phytotherapy
    • Studies
View Post
  • 15 min
  • Current status and future prospects

Cell and gene therapies in modern cardiology

    • Cardiology
    • Education
    • Genetics
    • RX
    • Studies
View Post
  • 14 min
  • Patient-oriented recommendations for action

Effect of heat on diabetes technology

    • RX
    • CME continuing education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Prevention and health care
    • Studies
View Post
  • 19 min
  • Cardiovascular risk and obesity

Pathomechanisms, secondary prevention and treatment options

    • RX
    • Cardiology
    • CME continuing education
    • Endocrinology and Diabetology
    • Nutrition
    • Sports Medicine
    • Studies
    • Training with partner
View Post
  • 6 min
  • Ventricular arrhythmias

Indication for ICD or WCD?

    • RX
    • Cardiology
    • Congress Reports
    • General Internal Medicine
    • Studies
View Post
  • 3 min
  • Early breast cancer

Overweight and obesity worsen the prognosis

    • Congress Reports
    • Gynecology
    • Oncology
    • Prevention and health care
    • RX
    • Studies
View Post
  • 8 min
  • Psoriasis treatment with biologics

What are the latest trends?

    • Congress Reports
    • Dermatology and venereology
    • Pharmacology and toxicology
    • Rheumatology
    • RX
    • Studies
View Post
  • 4 min
  • Flu vaccination for older people

Benefit of the high-dose influenza vaccine

    • Congress Reports
    • General Internal Medicine
    • Geriatrics
    • Infectiology
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Pathomechanisms, secondary prevention and treatment options
  • 2
    Effect of heat on diabetes technology
  • 3
    Improved quality of care aims for satisfied patients
  • 4
    Dr. ChatGPT: Large language models in everyday clinical practice
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.